Clinical application of adoptive T cell therapy in solid tumors

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 953-959

  Zang, Yi Wen ^a   Gu, Xiao Dong ^a   Xiang, Jian Bin ^a   Chen, Zong You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adoptive; Adoptive transfer; Antigens; Immunotherapy; Neoplasm

Indexed keywords

ALPHA2A INTERFERON; CARCINOEMBRYONIC ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CISPLATIN; GEMCITABINE; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; MELAN A; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL SURFACE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CARCINOMA; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE FREE SURVIVAL; DOWN REGULATION; GENE EXPRESSION; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; METASTATIC MELANOMA; NASOPHARYNX CARCINOMA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR REGRESSION; ADOPTIVE TRANSFER; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; NEOPLASMS;

ADOPTIVE TRANSFER; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84902314288     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.890496     Document Type: Review

References (72)

1. Rosenberg SA: Immunotherapy of cancer by systemic administration of lymphoid-cells plus interleukin-2. J Biol Response Mod, 1984; 3: 501-11
2. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleu-kin-2. Science, 1984; 225: 1487-89
3. Lafreniere R, Rosenberg SA: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol, 1985; 135: 4273-80
4. Rosenberg SA, Lotze MT, Muul LM et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombi-nant interleukin-2 to patients with metastatic cancer. N Engl J Med, 1985; 313: 1485-92
5. Hawkins MJ, Atkins MB, Dutcher JP et al: A phase II clinical trial of inter-leukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma. J Immunother Emphasis Tumor Immunol, 1994; 15: 74-78
6. Kimura H, Yamaguchi Y: Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer, 1995; 13: 31-44
7. Hirooka Y, Itoh A, Kawashima H et al: A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas, 2009; 38: e69-74
8. Dillman RO, Duma CM, Ellis RA et al: Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother, 2009; 32: 914-19
9. Law TM, Motzer RJ, Mazumdar M et al: Phase III randomized trial of inter-leukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 1995; 76: 824-32
10. Takayama T, Sekine T, Makuuchi M et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 2000; 356: 802-7
11. Rosenberg SA, Lotze MT, Yang JC et al: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst, 1993; 85: 622-32
12. Ferlazzo G, Scisca C, Iemmo R et al: Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleu-kin-2 for the treatment of liver tumors: a pilot study. J Immunother, 1997; 20: 158-63
13. Boiardi A, Silvani A, Rufni PA et al: Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother, 1994; 39: 193-97
14. Dillman RO, Duma CM, Schiltz PM et al: Intracavitary placement of autol-ogous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother, 2004; 27: 398-404
15. Vauleon E, Avril T, Collet B et al: Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol, 2010; 2010: 689171
16. Schmidt-Wolf IG, Negrin RS, Kiem HP et al: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent an-titumor cell activity. J Exp Med, 1991; 174: 139-49
17. Ochoa AC, Gromo G, Alter BJ et al: Long-term growth of lymphokine-acti-vated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol, 1987; 138: 2728-33
18. Jiang J, Wu C, Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med, 2013; 11: 83
19. Yu J, Ren X, Li H, et al: Synergistic efect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors. Cancer Biother Radiopharm, 2011; 26: 485-94
20. Liu L, Zhang W, Qi X et al: Randomized study of autologous cytokine-in-duced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res, 2012; 18: 1751-59
21. Weng DS, Zhou J, Zhou QM et al: Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother, 2008; 31: 63-71
22. Hui D, Qiang L, Jian W et al: A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis, 2009; 41: 36-41
23. Li JJ, Gu MF, Pan K et al: Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother, 2012; 35: 189-95
24. Li R, Wang C, Liu L et al: Autologous cytokine-induced killer cell immunother-apy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 2012; 61: 2125-33
25. Shi L, Zhou Q, Wu J et al: Efcacy of adjuvant immunotherapy with cyto-kine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother, 2012; 61: 2251-59
26. Zhao H, Fan Y, Li H et al: Immunotherapy with Cytokine-Induced Killer Cells as an Adjuvant Treatment for Advanced Gastric Carcinoma: A Retrospective Study of 165 Patients. Cancer Biother Radiopharm, 2013; 28: 303-9
27. Zhao Q, Zhang H, Li Y et al: Anti-tumor efects of CIK combined with oxali-platin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res, 2010; 29: 118
28. Jiang JT, Shen YP, Wu CP et al: Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol, 2010; 16: 6155-62
29. Hontscha C, Borck Y, Zhou H et al: Clinical trials on CIK cells: frst report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol, 2011; 137: 305-10
30. Rosenberg SA, Packard BS, Aebersold PM et al: Use of tumor-infltrating lymphocytes and interleukin-2 in the immunotherapy of patients with met-astatic melanoma. A preliminary report. N Engl J Med, 1988; 319: 1676-80
31. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol, 2009; 21: 233-40
32. Dudley ME, Wunderlich JR, Yang JC et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005; 23: 2346-57
33. Wu R, Forget MA, Chacon J et al: Adoptive T-cell therapy using autologous tumor-infltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J, 2012; 18: 160-75
34. Hong JJ, Rosenberg SA, Dudley ME et al: Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res, 2010; 16: 4892-98
35. Dembić Z, Haas W, Weiss S et al: Transfer of specifcity by murine alpha and beta T-cell receptor genes. Nature, 1986; 320: 232-38
36. Zhao Y, Zheng Z, Cohen CJ et al: High-efciency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther, 2006; 13: 151-59
37. Morgan RA, Dudley ME, Rosenberg SA: Adoptive cell therapy: genetic mod-ifcation to redirect efector cell specifcity. Cancer J, 2010; 16: 336-41
38. Morgan RA, Dudley ME, Wunderlich JR et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 2006; 314: 126-29
39. Johnson LA, Morgan RA, Dudley ME et al: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009; 114: 535-46
40. Parkhurst MR, Yang JC, Langan RC et al: T cells targeting carcinoembryon-ic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther, 2011; 19: 620-26
41. Robbins PF, Morgan RA, Feldman SA et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol, 2011; 29: 917-24
42. Morgan RA, Chinnasamy N, Abate-Daga D et al: Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother, 2013; 36: 133-51
43. McCormack E, Adams KJ, Hassan NJ et al: Bi-specifc TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunol Immunother, 2013; 62: 773-85
44. Hiasa A, Hirayama M, Nishikawa H et al: Long-term phenotypic, functional and genetic stability of cancer-specifc T-cell receptor (TCR) alpha beta genes transduced to CD8(+) T cells. Gene Ther, 2008; 15: 695-99
45. th Annual Meeting of the International Society for Biological Therapy of Cancer. J Immunother, 2010; 33: 860
46. Nakashima M, Sonoda K, Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med, 1999; 5: 938-42
47. Giaginis C, Giagini A, Theocharis S: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): a novel biomarker in the diagnosis and prognosis of human neoplasia. Histol Histopathol, 2009; 24: 761-76
48. Giaginis C, Demetriou N, Alexandrou P et al: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) expression in human benign and malignant thyroid lesions. Med Sci Monit, 2012; 18(4): BR123-29
49. Leisegang M, Wilde S, Spranger S et al: MHC-restricted fratricide of human lymphocytes expressing survivin-specifc transgenic T cell receptors. J Clin Invest, 2010; 120: 3869-77
50. Tassev DV, Cheng M, Cheung NK: Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specifc chimeric antigen receptor. Cancer Gene Ther, 2012; 19: 84-100
51. Kershaw MH, Westwood JA, Parker LL et al: A phase I study on adoptive immunotherapy using gene-modifed T cells for ovarian cancer. Clin Cancer Res, 2006; 12: 6106-15
52. Lamers CH, Sleijfer S, Vulto AG et al: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: frst clinical experience. J Clin Oncol, 2006; 24: e20-22
53. Lamers CH, Willemsen R, van Elzakker P et al: Immune responses to trans-gene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood, 2011; 117: 72-82
54. Park JR, Digiusto DL, Slovak M et al: Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuro-blastoma. Mol Ther, 2007; 15: 825-33
55. Till BG, Jensen MC, Wang J et al: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modifed autologous CD20-specifc T cells. Blood, 2008; 112: 2261-71
56. Pule MA, Savoldo B, Myers GD et al: Virus-specifc T cells engineered to co-express tumor-specifc receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med, 2008; 14: 1264-70
57. Louis CU, Savoldo B, Dotti G et al: Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood, 2011; 118: 6050-56
58. Savoldo B, Ramos CA, Liu E et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modifed T cells in lympho-ma patients. J Clin Invest, 2011; 121: 1822-26
59. Cheadle EJ, Rothwell DG, Bridgeman JS et al: Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from frst-generation chimeric antigen receptor T cells. Gene Ther, 2012; 19: 1114-20
60. Brentjens RJ, Rivière I, Park JH et al: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011; 118: 4817-28
61. Kalos M, Levine BL, Porter DL et al: T cells with chimeric antigen receptors have potent antitumor efects and can establish memory in patients with advanced leukemia. Sci Transl Med, 2011; 3: 95ra73
62. Kochenderfer JN, Wilson WH, Janik JE et al: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 2010; 116: 4099-102
63. Kochenderfer JN, Dudley ME, Feldman SA et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 2012; 119: 2709-20
64. Sadelain M, Brentjens R, Rivière I: The promise and potential pitfalls of chi-meric antigen receptors. Curr Opin Immunol, 2009; 21: 215-23
65. Gyobu H, Tsuji T, Suzuki Y et al: Generation and targeting of human tumor-specifc Tc1 and Th1 cells transduced with a lentivirus containing a chime-ric immunoglobulin T-cell receptor. Cancer Res, 2004; 64: 1490-95
66. Sasaki T, Ikeda H, Sato M et al: Antitumor activity of chimeric immunore-ceptor gene-modifed Tc1 and Th1 cells against autologous carcinoembry-onic antigen-expressing colon cancer cells. Cancer Sci, 2006; 97: 920-27
67. Wang H, Wei H, Zhang R et al: Genetically targeted T cells eradicate established breast cancer in syngeneic mice. Clin Cancer Res, 2009; 15: 943-50
68. Moeller M, Haynes NM, Kershaw MH et al: Adoptive transfer of gene-engineered CD4(+) helper T cells induces potent primary and secondary tumor rejection. Blood, 2005; 106: 2995-3003
69. Morgan RA, Yang JC, Kitano M et al: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther, 2010; 18: 843-51
70. Brentjens R, Yeh R, Bernal Y et al: Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther, 2010; 18: 666-68
71. Lamers CH, Sleijfer S, van Steenbergen S et al: Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther, 2013; 21: 904-12
72. Song DG, Ye Q, Carpenito C et al: In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimu-latory signaling through CD137 (4-1BB). Cancer Res, 2011; 71: 4617-27